Sex, Body Mass Index, and APOE4 Increase Plasma Phospholipid–Eicosapentaenoic Acid Response During an ω-3 Fatty Acid Supplementation: A Secondary Analysis
Abstract
BACKGROUND: ), age, and the presence of the apolipoprotein (APO) E-ε4 allele in response to the supplementation. OBJECTIVES: This secondary analysis aimed to determine the concentration of EPA and DHA within plasma PL and in the NEFA form after an ω-3 FA or a placebo supplementation and to investigate whether the factors change the response to the supplement. METHODS: A randomized, double-blind, placebo-controlled trial was conducted. Participants were randomly assigned to either an ω-3 FA supplement (DHA 0.8 g and EPA 1.7 g daily) or to a placebo for 6 mo. FAs from fasting plasma samples were extracted and subsequently separated into PLs with esterified FAs and NEFAs using solid-phase extraction. DHA and EPA concentrations in plasma PLs and as NEFAs were quantified using gas chromatography. RESULTS: EPA and DHA concentrations in the NEFA pool significantly increased by 31%-71% and 42%-82%, respectively, after 1 and 6 mo of ω-3 FA supplementation. No factors influenced plasma DHA and EPA responses in the NEFA pool. In the plasma PL pool, DHA increased by 83%-109% and EPA by 387%-463% after 1 and 6 mo of ω-3 FA supplementation. APOE4 carriers, females, and individuals with a BMI of ≤25 had higher EPA concentrations than noncarriers, males, and those with a BMI of >25, respectively. CONCLUSIONS: The concentration of EPA in plasma PLs are modulated by APOE4, sex, and BMI. These factors should be considered when designing clinical trials involving ω-3 FA supplementation. This trial was registered at clinicaltrials.gov as NCT01625195.
Related
- Strategic seasonal nutritional supplementation improves honey quality, colony performance, immune response, and pest resilience in Apis mellifera in Bangladesh
- Long-term dietary pyrroloquinoline quinone (PQQ) supplementation on growth, immune response, and antioxidant status in juvenile stellate sturgeon (Acipenser stellatus)
- Exploring the role of readthrough-inducing molecule 2,6-diaminopurine to increase immune response against cancer cells
- Omega-3 supplementation increases 13C-EPA but not 13C-DHA kinetics in healthy older adults after 13C-DHA single dose intake: A secondary analysis
- Eucalyptus grandis Auxin Response Factor 10 (EgrARF10) is associated with the modulation of secondary xylem cell wall chemistry
BibTeX
@article{loukil2026body,
title = {{Sex, Body Mass Index, and APOE4 Increase Plasma Phospholipid–Eicosapentaenoic Acid Response During an ω-3 Fatty Acid Supplementation: A Secondary Analysis}},
author = {Insaf Loukil and Ester Cisneros Aguilera and Annick Vachon and Pauline Léveillé and Mélanie Plourde},
journal = {Journal of Nutrition},
year = {2026},
month = oct,
doi = {10.1016/j.tjnut.2024.03.013},
url = {https://hal.science/hal-05790351v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Sex, Body Mass Index, and APOE4 Increase Plasma Phospholipid–Eicosapentaenoic Acid Response During an ω-3 Fatty Acid Supplementation: A Secondary Analysis
AU - Insaf Loukil
AU - Ester Cisneros Aguilera
AU - Annick Vachon
AU - Pauline Léveillé
AU - Mélanie Plourde
PY - 2026
DA - 2026/10/09
JO - Journal of Nutrition
DO - 10.1016/j.tjnut.2024.03.013
UR - https://hal.science/hal-05790351v1
AB - BACKGROUND: ), age, and the presence of the apolipoprotein (APO) E-ε4 allele in response to the supplementation. OBJECTIVES: This secondary analysis aimed to determine the concentration of EPA and DHA within plasma PL and in the NEFA form after an ω-3 FA or a placebo supplementation and to investigate whether the factors change the response to the supplement. METHODS: A randomized, double-blind, placebo-controlled trial was conducted. Participants were randomly assigned to either an ω-3 FA supplement (DHA 0.8 g and EPA 1.7 g daily) or to a placebo for 6 mo. FAs from fasting plasma samples were extracted and subsequently separated into PLs with esterified FAs and NEFAs using solid-phase extraction. DHA and EPA concentrations in plasma PLs and as NEFAs were quantified using gas chromatography. RESULTS: EPA and DHA concentrations in the NEFA pool significantly increased by 31%-71% and 42%-82%, respectively, after 1 and 6 mo of ω-3 FA supplementation. No factors influenced plasma DHA and EPA responses in the NEFA pool. In the plasma PL pool, DHA increased by 83%-109% and EPA by 387%-463% after 1 and 6 mo of ω-3 FA supplementation. APOE4 carriers, females, and individuals with a BMI of ≤25 had higher EPA concentrations than noncarriers, males, and those with a BMI of >25, respectively. CONCLUSIONS: The concentration of EPA in plasma PLs are modulated by APOE4, sex, and BMI. These factors should be considered when designing clinical trials involving ω-3 FA supplementation. This trial was registered at clinicaltrials.gov as NCT01625195.
SN - 0022-3166
SN - 0022-3166
ER -